• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-09-24

  This mouse study links SLC26A2 deficiency to excessive FGFR3 downstream signaling and tests both genetic and pharmacological inhibition as ways to mitigate skeletal abnormalities. Its combination of developmental models, chondrocyte assays, and in vivo imaging supports FGFR3 as a preclinical target, while leaving dose, timing, and human relevance unresolved.

• Plk1 Phosphorylates p31comet to Restrain MCC Disassembly

  2026-09-24

  The study identifies Polo-like kinase 1 (Plk1) as a direct, inhibitory regulator of p31comet, which works with TRIP13 to disassemble mitotic checkpoint complexes. By linking Plk1-dependent phosphorylation of p31comet to reduced disassembly activity, the authors propose a mechanism that helps preserve checkpoint signaling while it is needed.

• TAI-1 Hec1 Inhibitor: Applied Research Workflows

  2026-09-23

  TAI-1 offers a mechanism-led way to study mitotic disruption, cancer cell proliferation inhibition, and apoptotic cell death induction, with a reported 13.48 nM GI50 in K562 cells. This guide turns that benchmark into practical cell-line and organoid workflows while distinguishing established product data from exploratory retinoblastoma applications.

• Fludarabine: From DNA Stress to T-Cell Assays

  2026-09-23

  Explore how Fludarabine functions as a DNA synthesis inhibitor and how its effects can be measured across replication, apoptosis, and antigen-presentation assays. This article connects hematologic oncology models with emerging lymphodepletion and T-cell therapy research.

• Topotecan HCl in Cancer Assay Design

  2026-09-22

  Topotecan HCl enables mechanism-focused studies of replication-associated DNA damage, cytotoxicity, and treatment response across lung, breast, and prostate cancer models. This guide translates its topoisomerase 1 activity into practical exposure designs, paired viability and death readouts, and troubleshooting strategies for more interpretable data.

• MRSA Extracellular Vesicles and Oral Cancer Growth

  2026-09-22

  A 2026 study shows that extracellular vesicles from methicillin-resistant Staphylococcus aureus can promote oral squamous cell carcinoma proliferation through an ERK/c-Jun–IL-8–CXCR1–JAK/STAT5A signaling route. Its experimental design separates bacterial vesicle effects from direct infection and highlights why tumor-cell IL-8 signaling should not be conflated with CXCR2-dependent neutrophil chemotaxis.

• Allosteric Biosensor Tracks Native Protein Dynamics

  2026-09-21

  The reference study introduces circStep, an allosteric genetically encoded biosensor that translates endogenous protein binding into amplified fluorogenic RNA signals in living cells. By avoiding direct modification of the protein of interest, the approach enables real-time analysis of native localization, abundance changes, nucleocytoplasmic transport, and relocalization-dependent drug responses.

• PDK4-IN-1 hydrochloride: Assay Guide

  2026-09-21

  This scenario-driven guide explains how PDK4-IN-1 hydrochloride, SKU C8760, can support more interpretable cell viability, proliferation, and metabolism studies. It connects PDK4 biology with practical dosing, controls, data interpretation, and evidence-based product selection.

• Nonivamide: From TRPV1 Signal to Cancer Assay

  2026-09-20

  Explore how Nonivamide, a capsaicin analog, connects TRPV1 pharmacology with cancer cell growth inhibition. This article offers a paper-grounded framework for distinguishing receptor activation, mitochondrial apoptosis, and translational assay relevance.

• Forskolin in Pancreatic Organoid Assay Design

  2026-09-19

  Forskolin is a direct adenylate cyclase activator that can help researchers interrogate cAMP-dependent behavior in pancreatic ductal organoids. This article translates recent organoid-generation findings into practical decisions for dosing, controls, endpoint selection, and cross-model interpretation.

• Tigecycline: A Decision Framework for MDR Assays

  2026-09-18

  Tigecycline is a glycylcycline antibiotic with a distinctive 30S-targeting mechanism for multidrug-resistant bacterial research. This article develops an assay-centered framework linking phenotype, carbapenemase-gene localization, plasmid transfer, and infection-model interpretation.

• Chemotherapy Enhances Neoantigen T Cell Therapy

  2026-09-18

  The 2025 Cell Reports Medicine study identifies the KRAS.G12V-specific TCR T104 and shows that lymphodepleting chemotherapy improves neoantigen-directed T-cell activity by increasing immunoproteasome function, HLA-I expression, and peptide presentation. Its findings support treating chemotherapy not only as host conditioning, but also as a modulator of the tumor antigenic landscape in adoptive cell therapy.

• Psora 4: Kv1.3 Blocker Workflows

  2026-09-17

  Psora 4 is a selective Kv1.3 blocker for connecting membrane-potential control with T cell calcium signaling, effector-memory biology, and inflammatory disease models. Its greatest value comes from pairing concentration-response experiments with cell-state controls, kinetic measurements, and KCNE4-aware interpretation.

• H-89 for PKA Mechanism and Osteogenesis

  2026-09-17

  H-89 provides a rapid, reversible way to test whether PKA contributes to Wnt-driven metabolic and osteogenic responses. This guide translates its biochemical profile into dose-finding, time-resolved assays, and controls that distinguish PKA dependence from cytotoxicity or kinase off-target effects.

• Topotecan HCl Cancer Research Workflows

  2026-09-16

  Build more informative cancer drug assays with Topotecan HCl by separating growth inhibition from true cell killing. This guide connects short-exposure cytotoxicity studies with prolonged sphere, lung carcinoma, prostate, and translational workflows.

8636 records 1/576 page Next 12345 下5页 Last page